Get the app
US › Healthcare

Gossamer Bio Inc (GOSS)

US · Healthcare · Biotechnology

$8.77-1.35%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$9.2M
Revenue YoY
-19.6%
Net profit
$16.9M
EPS
$-0.20
EPS estimate
$-0.10
Net margin
182.9%

EPS came in at -0.20 against a street estimate of -0.10 — a miss of 100.0%.

Key statistics

Market cap
$59.7M
Forward P/E
0.0
P/B
2.66
Book value
$-15.39
EPS (TTM)
$-52.80
52-week high
$309.60
52-week low
$8.77
50-day MA
$12.34
200-day MA
$56.27
Beta
2.21

Analyst view

Analysts rate Gossamer Bio Inc a buy (3 buy, 3 hold, 1 sell out of 7) with an average price target of $82.48.

Shareholding

Insiders
1.43%
Institutions
85.82%

Largest institutional holders

FundStake
D. E. Shaw & Co LP8.37%
DeepCurrents Investment Group LLC7.70%
Context Capital Management LLC5.92%
Worth Venture Partners, LLC5.11%
Kalehua Capital Management LLC4.56%
AQR Capital Management LLC3.19%
GSA Capital Partners LLP3.06%
Wolverine Asset Management LLC2.64%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gossamer Bio Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.